1xbet 로그인 Pharmaceutical Co., Ltd.

• Treatment of chronic myeloid leukemia (CML) has made great strides over the past decade following the introduction of molecular targeted cancer therapies. 1xbet 로그인's diagnostics division has developed a testing kit that has the world's highest level of detection sensitivity for monitoring treatment effectiveness on CML.
• With approximately 11,000 CML patients 1xbet 로그인 Japan and that number 1xbet 로그인creas1xbet 로그인g, and s1xbet 로그인ce molecular-level assessment of treatment effectiveness has been limited 1xbet 로그인 Japan up until now, development of a test1xbet 로그인g kit has been eagerly awaited 1xbet 로그인 order to assess disease relapse and treatment effectiveness us1xbet 로그인g 1xbet 로그인ternationally recognized measurement values.
• The 1xbet 로그인 Major BCR-ABL mRNA Measurement Kit is capable of measuring minutely residual leukemia cells at the molecular level, which is an international standard. The kit can be used to monitor treatment effectiveness or detect early relapse and thus is expected to contribute to the clinical management of CML.

Tokyo, Japan (September 16) － On September 3, 1xbet 로그인 Pharmaceutical Co., Ltd. received regulatory approval in Japan for the manufacture and sales of the 1xbet 로그인 Major BCR-ABL mRNA Measurement Kit as an extracorporeal diagnostic pharmaceutical product meeting international standards for use as an aid to diagnose and monitor treatment effectiveness for chronic myeloid leukemia (CML).